Skip to main content

Table 3 Laboratory parameters in all dogs, healthy dogs and dogs with different stages of MMVD

From: Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease

  All dogs Healthy Stage B1 Stage B2 Stage C
Number 149 49 45 13 42
UREA (mg/dL) 39 (31–49.28) 33 (27.93–40-50) § 35.16 ± 10.60 58 ± 25.85 49 (38.68–68.04)
SCr (mg/dL) 0.92 (0.80–1.10) 0.91 ± 0.20 0.89 ± 0.18 1.04 ± 0.32 1 (0.80–1.18)
USG 1036 (1020.50–1052) 1046.98 ± 18.41 § 1042.07 ± 16.16 § 1039.69 ± 20.50 1019 (1011.50–1028.50)
UP/UC 0.12 (0.04–0.27) 0.07 (0.03–0.12) ‡§ 0.15 (0.06–0.24) 0.20 (0.10–0.41) 0.25 (0.35–0.69)
UAldo:C (μg/g) 1.86 (0.88–3.77) 1.75 (0.83–4.02) 1.75 (0.73–3.13) 1.95 (0.85–4.65) 2.03 (1.16–4.85)
  1. UREA Serum urea, SCr Serum creatinine, USG Urine specific gravity, UP/UC Urinary protein-to-creatinine ratio, UAldo:C Urinary aldosterone-to-creatine ratio
  2. Data are reported as mean ± standard deviation for normally distributed variables and median (interquartile range) for non-normally distributed variables
  3. †values significantly differ (p < 0.05) from stage B1; ‡values significantly differ (p < 0.05) from stage B2; §values significantly differ (p < 0.05) from stage C